GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

CHF6333   Click here for help

GtoPdb Ligand ID: 14269

Synonyms: CHF 6333 | CHF-6333 | Example 47 (cation) [US9828382] [1]
Compound class: Synthetic organic
Comment: CHF6333 is a lung-restricted (by inhalation) neutrophil elastase (NE) inhibitor [2]. It is formulated as a salt (e.g., as the methanesulfonate), and strictly this entry represents the CHF6333 cation. Local delivery to the lung is intended to minimise systemic exposure and off-target toxicity. NE inhibition is proposed to rebalance elevated NE activity that underlies disruption of vascular endothelium, vascular permeability and tissue damage in chronic inflammatory lung disease.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 8
Topological polar surface area 98.03
Molecular weight 541.55
XLogP 2.02
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1=C([C@@H](C2=CC=C(C=C2CC[N+](C)(C)C)C#N)N3C(=NNC3=O)N1C4=CC(=CC=C4)C(F)(F)F)C(=O)OC
Isomeric SMILES CC1=C([C@H](N2C(=O)NN=C2N1C3=CC=CC(=C3)C(F)(F)F)C4=C(C=C(C=C4)C#N)CC[N+](C)(C)C)C(=O)OC
InChI InChI=1S/C27H27F3N6O3/c1-16-22(24(37)39-5)23(21-10-9-17(15-31)13-18(21)11-12-36(2,3)4)35-25(32-33-26(35)38)34(16)20-8-6-7-19(14-20)27(28,29)30/h6-10,13-14,23H,11-12H2,1-5H3/p+1/t23-/m1/s1
InChI Key IHTRPSMRGYWUIM-HSZRJFAPSA-O

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
CHF6333 is a clinical candidate that is proposed for the treatment of bronchiectasis.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03056326 A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects Phase 1 Interventional Chiesi Farmaceutici S.p.A.
NCT04010799 A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis Phase 1 Interventional Chiesi Farmaceutici S.p.A.
NCT06166056 A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis Phase 1/Phase 2 Interventional Chiesi Farmaceutici S.p.A.